IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, located in South San Francisco and San Diego, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery.

Recent News

Jan 4, 2018, J.P. Morgan's 36th Annual Healthcare Conference on Wednesday, January 10, 2018.  IDEAYA Biosciences to present at J.P. Morgan's Annual Healthcare Conference on Wednesday, January 10 at 1:30pm PT.

(PDF Download)

May 4, 2016, BioWorld Today Cover Story.  Capital Ideaya: $46M take propels synthetic lethality; gene pairs kicked upstairs

(PDF download)

Corporate Documents

IDEAYA 2 Page Summary

(PDF download)

IDEAYA Website Print Out

(PDF download)

Our Science

Synthetic Lethality (SL) is a concept first identified in the model genetic system Drosophila melanogaster (fruit fly) and recapitulated in yeast and other organisms.